Table 1.

 Inclusion criteria for studies comparing second generation antidepressant with cognitive behavioral therapy

Parameter	Criteria
Population	Adult (18 years or older) outpatients with major depressive disorder during initial treatment attempt for current episode
Interventions	Second generation antidepressants approved for treatment of major depressive disorder by the US Food and Drug Administration: bupropion, citalopram, desvenlafaxine, duloxetine, fluoxetine, escitalopram, fluvoxamine, levomilnacipran, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, venlafaxine, vilazodone, vortioxetine
	Cognitive behavioral therapies as classified by Cochrane Collaborative Depression, Anxiety and Neurosis Group’s framework27
Outcomes	Benefits: response, remission, speed of response, speed of remission, relapse, quality of life, functional capacity, suicidal ideas or behaviors, hospital admission
	Harms: overall adverse events, withdrawals because of adverse events, serious adverse events, specific adverse events (including hyponatremia, seizures, suicidal ideas or behaviors, hepatotoxicity, weight gain, gastrointestinal symptoms, sexual side effects), withdrawals because of specific adverse events
Study designs	Benefits: randomized controlled trials, systematic reviews, and meta-analyses
	In addition for harms: non-randomized controlled trials, prospective controlled cohort studies, retrospective controlled cohort studies, case-control studies, all with minimum sample size of 500 participants